Last reviewed 2026-04-20 · How we verify

Pegasys

At a glance

Approved indications

• Chronic hepatitis C
• Chronic type B viral hepatitis

Common side effects

• Depression
• Insomnia
• Irritability
• Anxiety
• Fatigue
• Pyrexia
• Myalgia
• Headache
• Rigors
• Anorexia
• Nausea
• Vomiting

Serious adverse events

• Bacterial infection
• Hepatic decompensation
• Depression
• Suicide
• Drug abuse/overdose
• Suicidal ideation
• Autoimmune phenomena
• Pancreatitis
• Pulmonary embolism
• Thrombotic thrombocytopenic purpura

Key clinical trials

• VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
• Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort (NA)
• A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
• Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
• Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.